Despite promising clinical data, copyright's Vyndamax, a therapy for hereditary transthyretin-mediated amyloidosis (hATTR), is facing substantial opposition from PBMs. Such companies are frequently erecting obstacles to access, like steep expense restrictions and prior authorization that restrict consumer access. Market indicate that such access hu